Yeast Model of Amyloid- β and Tau Aggregation in Alzheimer's Disease

Journal of Alzheimer's Disease

Volumn 47, Issue 1, 2015, Pages 9-16

  Moosavi, Behrooz ^a   Mousavi, Bibimaryam ^b   Macreadie, Ian G ^c  

^a CENTRAL CHINA NORMAL UNIVERSITY   (China)

^b WUHAN UNIVERSITY OF TECHNOLOGY   (China)

^c RMIT UNIVERSITY   (Australia)

Author keywords

Alzheimer's disease; Amyloid; Protein aggregation; Tau protein; Yeasts

Indexed keywords

ACTIN; ALPHA SECRETASE; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; INSULINASE; MEMBRANE METALLOENDOPEPTIDASE; MESSENGER RNA; REACTIVE OXYGEN METABOLITE; TAU PROTEIN;

ALTERNATIVE RNA SPLICING; ALZHEIMER DISEASE; CYTOSOL; NONHUMAN; OLIGOMERIZATION; OXIDATIVE STRESS; POLYMERIZATION; PRIORITY JOURNAL; PROTEIN AGGREGATION; REVIEW; YEAST; ANIMAL; DISEASE MODEL; HUMAN; METABOLISM;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; TAU PROTEINS; YEASTS;

EID: 84940932191     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-150173     Document Type: Review

References (80)

1. Prince M, Bryce R, Albanese E, Wimo A, Ribeiro W, Ferri CP (2013) The global prevalence of dementia: A systematic review and metaanalysis. Alzheimers Dement 9, 63-75.e62.
2. Selkoe DJ, PodlisnyMB (2002) Deciphering the genetic basis of Alzheimer's disease. Annu Rev Genomics Hum Genet 3, 67-99.
3. Dong S, Duan Y, Hu Y, Zhao Z (2012) Advances in the pathogenesis of Alzheimer's disease: A re-evaluation of amyloid cascade hypothesis. Transl Neurodegener 1, 1-12.
4. Irie K, Murakami K, Masuda Y, Morimoto A, Ohigashi H, Ohashi R, Takegoshi K, Nagao M, Shimizu T, Shirasawa T (2005) Structure of -amyloid fibrils and its relevance to their neurotoxicity: Implications for the pathogenesis of Alzheimer's disease. J Biosci Bioeng 99, 437-447.
5. Kamenetz F, Tomita T, Hsieh H, Seabrook G, Borchelt D, Iwatsubo T, Sisodia S, Malinow R (2003) APP processing and synaptic function. Neuron 37, 925-937.
6. Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science 297, 353-356.
7. Knobloch M, Konietzko U, Krebs DC, Nitsch RM (2007) Intracellular A- and cognitive deficits precede beta-amyloid deposition in transgenic arc A- mice. Neurobiol Aging 28, 1297-1306.
8. Lee EB, Leng LZ, Zhang B, Kwong L, Trojanowski JQ, Abel T, Lee VM (2006) Targeting amyloid- peptide (A-) oligomers by passive immunization with a conformation-selective monoclonal antibody improves learning and memory in A- precursor protein (APP) transgenic mice. J Biol Chem 281, 4292-4299.
9. Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, Brett FM, Farrell MA, Rowan MJ, Lemere CA, Regan CM, Walsh DM, Sabatini BL, Selkoe DJ (2008) Amyloid- protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med 14, 837-842.
10. Walsh DM, Tseng BP, Rydel RE, Podlisny MB, Selkoe DJ (2000) The oligomerization of amyloid-protein begins intracellularly in cells derived from human brain. Biochemistry 39, 10831-10839.
11. Golde TE, Schneider LS, Koo EH (2011) Anti-A- therapeutics in Alzheimer's disease: The need for a paradigm shift. Neuron 69, 203-213.
12. Hardy J (2009) The amyloid hypothesis for Alzheimer's disease: A critical reappraisal. J Neurochem 110, 1129-1134.
13. Kim. J, Chakrabarty P, Hanna A, March A, Dickson D, Borchelt D, Golde T, Janus C (2013) Normal cognition in transgenic BRI2-Abeta mice. Mol Neurodegener 8, 15.
14. Tamayev R, Matsuda S, Arancio O, D'Adamio L (2012) - but not -secretase proteolysis of APP causes synaptic and memory deficits in a mouse model of dementia. EMBO Mol Med 4, 171-179.
15. Klein WL, StineWBJr., Teplow DB (2004) Small assemblies of unmodified amyloid -protein are the proximate neurotoxin in Alzheimer's disease. Neurobiol Aging 25, 569-580.
16. LaFerla FM, Oddo S (2005) Alzheimer's disease: A-, tau and synaptic dysfunction. Trends Mol Med 11, 170-176.
17. Walsh DM,Selkoe DJ (2004) Deciphering the molecular basis ofmemoryfailure inAlzheimer's disease.Neuron44,181-193.
18. Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, Morgan TE, Rozovsky I, Trommer B, Viola KL, Wals P, Zhang C, Finch CE, Krafft GA, KleinWL(1998) Diffusible, nonfibrillar ligands derived from A-1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci U S A 95, 6448-6453.
19. Oda T, Pasinetti GM, Osterburg HH, Anderson C, Johnson SA, Finch CE (1994) Purification and Characterization of Brain Clusterin. Biochem Biophys Res Commun 204, 1131-1136.
20. Hayden E, Teplow D (2013) Amyloid beta-protein oligomers and Alzheimer's disease. Alzheimers Res Ther 5, 60.
21. Berhanu WM, Masunov AE (2010) Natural polyphenols as inhibitors of amyloid aggregation. Molecular dynamics study of GNNQQNY heptapeptide decamer. Biophys Chem 149, 12-21.
22. Misiti F, Sampaolese B, Mezzogori D, Orsini F, Pezzotti M, Giardina B, Clementi ME (2006) Protective effect of rhubarb derivatives on amyloid beta (1-42) peptide-induced apoptosis in IMR-32 cells: A case of nutrigenomic. Brain Res Bull 71, 29-36.
23. Nakdook W, Khongsombat O, Taepavarapruk P, Taepavarapruk N, Ingkaninan K (2010) The effects of Tabernaemontana divaricata root extract on amyloid -peptide 25-35 peptides induced cognitive deficits in mice. J Ethnopharmacol 130, 122-126.
24. Qu B, Boyer PJ, Johnston SA, Hynan LS, Rosenberg RN (2006) A-42 gene vaccination reduces brain amyloid plaque burden in transgenic mice. J Neurol Sci 244, 151-158.
25. Solomon B, Frenkel D (2010) Immunotherapy for Alzheimer's disease. Neuropharmacology 59, 303-309.
26. Wang H-Q, Sun X-B, Xu Y-X, Zhao H, Zhu Q-Y, Zhu C-Q (2010) Astaxanthin upregulates heme oxygenase-1 expression through ERK1/2 pathway and its protective effect against beta-amyloid-induced cytotoxicity in SH-SY5Y cells. Brain Res 1360, 159-167.
27. Reinhard C, Hebert SS, De Strooper B (2005) The amyloid- precursor protein: Integrating structure with biological function. EMBO J 24, 3996-4006.
28. Wong BX, Tsatsanis A, Lim LQ, Adlard PA, Bush AI, Duce JA (2014) -amyloid precursor protein does not possess ferroxidase activity but does stabilize the cell surface ferrous iron exporter ferroportin. PLoS One 9, e114174.
29. Zheng H, Koo E (2006) The amyloid precursor protein: Beyond amyloid. Mol Neurodegener 1, 5.
30. Chacińska A, Wózny W, Boguta M, Misicka A, Brzyska M, ElbaumD(2002) Effects of beta-amyloid on proliferation and morphology of yeast Saccharomyces cerevisiae. Lett Pept Sci 9, 197-201.
31. Franssens V, Bynens T, Van den Brande J, Vandermeeren K, Verduyckt M,Winderickx J (2013) The benefits of humanized yeast models to study Parkinson's disease. Oxid Med Cell Longev 2013, 9.
32. Khurana V, Lindquist S (2010) Modelling neurodegeneration in Saccharomyces cerevisiae: Why cook with baker's yeast? Nat Rev Neurosci 11, 436-449.
33. Miller-Fleming L, Giorgini F, Outeiro TF (2008) Yeast as a model for studying human neurodegenerative disorders. Biotechnol J 3, 325-338.
34. Pereira C, Bessa C, Soares J, Leão M, Saraiva L (2012) Contribution of yeast models to neurodegeneration research. J Biomed Biotechnol 2012, 941232.
35. Tenreiro S, Munder MC, Alberti S, Outeiro TF (2013) Harnessing the power of yeast to unravel the molecular basis of neurodegeneration. J Neurochem 127, 438-452.
36. Bharadwaj P,Waddington L,Varghese J, Macreadie IG (2008) A new method to measure cellular toxicity of non-fibrillar and fibrillar Alzheimer's A- using yeast. J Alzheimers Dis 13, 147-150.
37. Porzoor A, Caine JM, Macreadie IG (2014) Pretreatment of chemically-synthesized A-42 affects its biological activity in yeast. Prion 8, 404-410.
38. Currais A, Hortobágyi T, Soriano S (2009) The neuronal cell cycle as a mechanism of pathogenesis in Alzheimer's disease. Aging 1, 363-371.
39. Huang C-T, Yang D-I (2011) Roles of Id1 in A-induced cell cycle re-entry in postmitotic neurons. Alzheimers Dement 7, S406.
40. McShea A, Lee HG, Petersen RB, Casadesus G, Vincent I, Linford NJ, Funk J-O, Shapiro RA, Smith MA (2007) Neuronal cell cycle re-entry mediates Alzheimer disease-type changes. Biochim Biophys Acta 1772, 467-472.
41. Moh C, Kubiak J, Bajic V, Zhu X, Smith M, Lee HG (2011) Cell cycle deregulation in the neurons of Alzheimer's disease. In Cell Cycle in Development, Kubiak JZ, ed. Springer Berlin Heidelberg, pp. 565-576.
42. Lai AY, McLaurin J (2011) Mechanisms of amyloid-beta peptide uptake by neurons: The role of lipid rafts and lipid raft-associated proteins. Int J Alzheimers Dis 2011, 11.
43. LaFerla FM, Green KN, Oddo S (2007) Intracellular amyloid- - in Alzheimer's disease. Nat Rev Neurosci 8, 499-509.
44. Caine J, Sankovich S, Antony H, Waddington L, Macreadie P, Varghese J, Macreadie I (2007) Alzheimer's A- fused to green fluorescent protein induces growth stress and a heat shock response. FEMS Yeast Res 7, 1230-1236.
45. Macreadie I, Lotfi-Miri M, Mohotti S, Shapira D, Bennett L, Varghese J (2008) Validation of folate in a convenient yeast assay suited for identification of inhibitors of Alzheimer's amyloid- aggregation. J Alzheimers Dis 15, 391-396.
46. Bagriantsev S, Liebman S (2006) Modulation of A-42 low-n oligomerization using a novel yeast reporter system. BMC Biol 4, 32.
47. Park SK, Pegan SD, Mesecar AD, Jungbauer LM, LaDu MJ, Liebman SW (2011) Development and validation of a yeast high-throughput screen for inhibitors of A-42 oligomerization. Dis Model Mech 4, 822-831.
48. von der Haar T, Josse L, Wright P, Zenthon J, Tuite MF (2007) Development of a novel yeast cell-based system for studying the aggregation of Alzheimer's disease-associated A- peptides in vivo. Neurodegener Dis 4, 136-147.
49. Thinakaran G, Koo EH (2008) Amyloid Precursor Protein Trafficking, Processing, and Function. J Biol Chem 283, 29615-29619.
50. Treusch S, Hamamichi S, Goodman JL, Matlack KE, Chung CY, Baru V, Shulman JM, Parrado A, Bevis BJ, Valastyan JS, Han H, Lindhagen-Persson M, Reiman EM, Evans DA, Bennett DA, Olofsson A, DeJager PL, Tanzi RE, Caldwell KA, Caldwell GA, Lindquist S (2011) Functional links between A- toxicity, endocytic trafficking, and Alzheimer's disease risk factors in yeast. Science 334, 1241-1245.
51. Matlack KES, Tardiff DF, Narayan P, Hamamichi S, Caldwell KA, Caldwell GA, Lindquist S (2014) Clioquinol promotes the degradation of metal-dependent amyloid-(A-) oligomers to restore endocytosis and ameliorate A- toxicity. Proc Natl Acad Sci U S A 111, 4013-4018.
52. D'Angelo F, Vignaud H, Di Martino J, Salin B, Devin A, Cullin C, Marchal C (2013) A yeast model for amyloid- aggregation exemplifies the role of membrane trafficking and PICALM in cytotoxicity. Dis Model Mech 6, 206-216.
53. MandelkowE-M,MandelkowE (2012) Biochemistry and cell biology of tau protein in neurofibrillary degeneration. Cold Spring Harb Perspect Med 2, a006247.
54. Roy S, Zhang B, Lee VY, Trojanowski J (2005) Axonal transport defects:Acommon theme in neurodegenerative diseases. Acta Neuropathol 109, 5-13.
55. Goedert M, Spillantini MG, Jakes R, Rutherford D, Crowther RA (1989) Multiple isoforms of human microtubuleassociated protein tau: Sequences and localization in neurofibrillary tangles of Alzheimer's disease. Neuron 3, 519-526.
56. Goedert M, Spillantini MG, Potier MC, Ulrich J, Crowther RA (1989) Cloning and sequencing of the cDNA encoding an isoform of microtubule-associated protein tau containing four tandem repeats: Differential expression of tau proteinmRNAs in human brain. EMBO J 8, 393-399.
57. Himmler A, Drechsel D, Kirschner MW, Martin DW (1989) Tau consists of a set of proteins with repeated C-terminal microtubule-binding domains and variable N-terminal domains. Mol Cell Biol 9, 1381-1388.
58. Drewes G, Trinczek B, Illenberger S, Biernat J, Schmitt- Ulms G, Meyer HE, Mandelkow E-M, Mandelkow E (1995) Microtubule-associated protein/microtubule affinityregulating kinase (p110mark). J Biol Chem 270, 7679-7688.
59. Berger Z, Roder H, Hanna A, Carlson A, Rangachari V, Yue M, Wszolek Z, Ashe K, Knight J, Dickson D, Andorfer C, Rosenberry TL, Lewis J, Hutton M, Janus C (2007) Accumulation of pathological tau species and memory loss in a conditional model of tauopathy. J Neurosci 27, 3650-3662.
60. Bretteville A, Planel E (2008) Tau aggregates: Toxic, inert, or protective species? J Alzheimers Dis 14, 431-436.
61. Chesser A, Pritchard S, Johnson GVW (2013) Tau clearance mechanisms and their possible role in the pathogenesis of Alzheimer disease. Frontiers Neurol 4, 122.
62. Spires-Jones TL, Stoothoff WH, de Calignon A, Jones PB, Hyman BT (2009) Tau pathophysiology in neurodegeneration: A tangled issue. Trends Neurosci 32, 150-159.
63. De Vos A, Anandhakumar J, Van den Brande J, Verduyckt M, Franssens V, Winderickx J, Swinnen E (2011) Yeast as a model system to study tau biology. Intl J Alzheimers Dis 2011, 428970.
64. Morais VA, De Strooper B (2010) Mitochondria dysfunction and neurodegenerative disorders: Cause or consequence. J Alzheimers Dis 20(Suppl 2), S255-S263.
65. Moreira PI, Carvalho C, Zhu X, Smith MA, Perry G (2010) Mitochondrial dysfunction is a trigger of Alzheimer's disease pathophysiology. Biochim Biophys Acta 1802, 2-10.
66. Patten DA, Germain M, Kelly MA, Slack RS (2010) Reactive oxygen species: Stuck in the middle of neurodegeneration. J Alzheimers Dis 20(Suppl 2), S357-S367.
67. Perry G, Cash AD, Smith MA (2002) Alzheimer disease and oxidative stress. J Biomed Biotechnol 2, 120-123.
68. Zhao Y, Zhao B (2013) Oxidative stress and the pathogenesis of Alzheimer's disease. Oxid Med Cell Longev 2013, 316523.
69. Eckert A, Nisbet R, Grimm A, Gotz J (2014) March separate, strike together-role of phosphorylated TAU in mitochondrial dysfunction in Alzheimer's disease. Biochim Biophys Acta 1842, 1258-1266.
70. Eckert A, Schulz K, Rhein V, Götz J (2010) Convergence of amyloid- and tau pathologies on mitochondria in vivo. Mol Neurobiol 41, 107-114.
71. Mondragon-Rodriguez S, Perry G, Zhu X, Moreira PI, Acevedo-Aquino MC,Williams S (2013) Phosphorylation of tau protein as the link between oxidative stress, mitochondrial dysfunction, and connectivity failure: Implications for Alzheimer's disease. Oxid Med Cell Longev 2013, 940603.
72. Braak H, Zetterberg H, Del Tredici K, Blennow K (2013) Intraneuronal tau aggregation precedes diffuse plaque deposition, but amyloid- changes occur before increases of tau in cerebrospinal fluid. Acta Neuropathol 126, 631-641.
73. Oddo S, Caccamo A, Kitazawa M, Tseng BP, LaFerla FM (2003) Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer's disease. Neurobiol Aging 24, 1063-1070.
74. Lonskaya I, Hebron M, Chen W, Schachter J, Moussa C (2014) Tau deletion impairs intracellular beta-amyloid-42 clearance and leads to more extracellular plaque deposition in gene transfer models. Mol Neurodegener 9, 46.
75. Rapoport M, Dawson HN, Binder LI, Vitek MP, Ferreira A (2002) Tau is essential to -amyloid-induced neurotoxicity. Proc Natl Acad Sci U S A 99, 6364-6369.
76. Huang H-C, Jiang Z-F (2009) Accumulated amyloid- peptide and hyperphosphorylated tau protein: Relationship and links in Alzheimer's disease. J Alzheimers Dis 16, 15-27.
77. Mairet-Coello G, Courchet J, Pieraut S, Courchet V, Maximov A, Polleux F (2013) The CAMKK2-AMPK kinase pathway mediates the synaptotoxic effects of A- oligomers through tau phosphorylation. Neuron 78, 94-108.
78. Vandebroek T, Terwel D, Vanhelmont T, Gysemans M, Van Haesendonck C, Engelborghs Y,Winderickx J, Van Leuven F (2006) Microtubule binding and clustering of human tau-4R and tau-P301L proteins isolated from yeast deficient in orthologues of glycogen synthase kinase-3- or cdk5. J Biol Chem 281, 25388-25397.
79. Vandebroek T, Vanhelmont T, Terwel D, Borghgraef P, Lemaire K, Snauwaert J,Wera S, Van Leuven F,Winderickx J (2005) Identification and isolation of a hyperphosphorylated, conformationally changed intermediate of human protein tau expressed in yeast. Biochemistry 44, 11466-11475.
80. Vanhelmont T, Vandebroek T, De Vos A, Terwel D, Lemaire K, Anandhakumar J, Franssens V, Swinnen E, Van Leuven F, Winderickx J (2010) Serine-409 phosphorylation and oxidative damage define aggregation of human protein tau in yeast. FEMS Yeast Res 10, 992-1005.